Crestor and Zolpidem Interaction: What the Evidence Actually Shows

Why This Combination Comes Up So Often

Statins and sleep aids rank among the most co-prescribed medication classes in the United States. Rosuvastatin held over 29 million dispensed prescriptions in 2023, making it the fourth most-prescribed drug nationally according to ClinCalc data derived from MEPS survey analyses. Zolpidem, meanwhile, remains the most commonly prescribed hypnotic in the U.S., with an estimated 5.7 million adults filling at least one prescription per year per CDC National Health Statistics Reports [1][2].

The overlap is predictable. Hyperlipidemia prevalence rises sharply after age 40, and insomnia complaints increase in the same demographic window. A 2019 analysis of Medicare Part D claims found that 18.4% of statin users over age 65 also received at least one sedative-hypnotic prescription within the same calendar year [3]. Patients searching "Crestor and zolpidem interaction" are doing exactly what pharmacists hope they will do: checking before assuming safety.

The short answer is reassuring. These two drugs travel through largely separate metabolic and pharmacologic channels. But the full picture requires understanding why that is the case, what edge-case scenarios could theoretically shift the risk, and what monitoring still applies.

Metabolic Pathways: Where These Drugs Diverge

Rosuvastatin is a hydrophilic statin with unusually low hepatic CYP dependence. The FDA-approved prescribing information for Crestor states that approximately 10% of a rosuvastatin dose undergoes CYP2C9-mediated metabolism, with CYP2C19 playing a negligible secondary role [4]. The drug's primary elimination route is biliary excretion of unchanged parent compound. This metabolic profile distinguishes rosuvastatin from lipophilic statins like simvastatin and atorvastatin, which depend heavily on CYP3A4 and carry far higher interaction burdens.

Zolpidem follows a different highway entirely. The zolpidem prescribing information identifies CYP3A4 as the primary metabolic enzyme, responsible for approximately 61% of zolpidem clearance [5]. CYP1A2 contributes roughly 22%, CYP2C9 about 14%, and CYP2D6 a minor 3%.

The only shared enzyme is CYP2C9. That 14% contribution to zolpidem clearance and 10% contribution to rosuvastatin metabolism create a theoretical point of contact. In practice, neither drug inhibits or induces CYP2C9 at therapeutic concentrations. A 2017 in-vitro study using human liver microsomes confirmed that rosuvastatin at concentrations up to 100 times the clinical Cmax produced no measurable inhibition of CYP2C9-mediated diclofenac 4'-hydroxylation [6].

The absence of CYP3A4 involvement in rosuvastatin metabolism is the central reason this combination carries low pharmacokinetic risk. Drugs that inhibit CYP3A4 (ketoconazole, clarithromycin, certain HIV protease inhibitors) can raise zolpidem plasma levels substantially. Rosuvastatin does not.

Transporter-Level Interactions: The Other Half of Drug Disposition

Metabolic enzymes are only part of the interaction story. Rosuvastatin depends on hepatic uptake transporters, specifically OATP1B1 and OATP1B3, to reach its intracellular site of action inside hepatocytes [7]. The drug is also a substrate of the efflux transporter BCRP (breast cancer resistance protein). Inhibitors of these transporters (cyclosporine, certain protease inhibitors, gemfibrozil) can raise rosuvastatin exposure by 2- to 7-fold, as documented in pharmacokinetic studies indexed on PubMed [7].

Zolpidem has no known activity as an inhibitor or substrate of OATP1B1, OATP1B3, or BCRP. The International Transporter Consortium's published DDI guidance does not flag zolpidem as a perpetrator of transporter-mediated interactions [8]. This effectively closes the second potential interaction pathway.

Pharmacodynamic Assessment: Do the Effects Overlap?

Pharmacokinetic neutrality does not always guarantee safety. Two drugs can interact at the receptor or tissue level even when their blood concentrations remain unchanged. This pharmacodynamic dimension matters especially for combinations involving CNS-active agents.

Rosuvastatin works by competitively inhibiting HMG-CoA reductase in hepatocytes. It has no known CNS receptor activity, does not cross the blood-brain barrier in meaningful concentrations (a benefit of its hydrophilicity), and produces no sedation, cognitive impairment, or psychomotor effects at any approved dose [4].

Zolpidem selectively binds the alpha-1 subunit of GABA-A receptors, producing sedation and sleep initiation. Its pharmacodynamic concerns center on additive CNS depression when combined with other sedating agents: benzodiazepines, opioids, alcohol, antihistamines, or muscle relaxants [5].

The 2023 American Geriatrics Society Beers Criteria flags zolpidem in combination with other CNS depressants as potentially inappropriate in older adults, but does not extend this warning to statins [9]. Dr. Todd Semla, a clinical pharmacist and co-author of the Beers Criteria update, has noted: "The concern with zolpidem in older adults centers on additive sedation with other CNS-active medications, falls risk, and next-morning impairment. Statins do not contribute to that pharmacodynamic burden" [9].

There is no additive sedation mechanism between these two medications.

What the DDI Databases Say

Commercial drug-drug interaction databases assign severity and evidence ratings that guide clinical decision-making. Here is how major platforms classify the rosuvastatin-zolpidem combination:

Lexicomp: No interaction identified. Rosuvastatin and zolpidem do not appear as an interacting pair in the Lexi-Interact database.

Micromedex: No listed interaction. The database does not generate an alert when these two drugs are entered together.

Epocrates: No interaction flagged. The combination does not trigger a clinical advisory.

Clinical Pharmacology (Elsevier): No interaction listed.

This consensus across four independent databases reflects the absence of published case reports, pharmacokinetic studies, or mechanistic rationale supporting a clinically significant interaction between these drugs.

Contrast this with rosuvastatin's documented interactions with cyclosporine (contraindicated per FDA label; rosuvastatin AUC increased 7.1-fold), gemfibrozil (rosuvastatin AUC increased 1.9-fold), and lopinavir/ritonavir (rosuvastatin AUC increased 2.1-fold) [4]. These interactions have clear mechanistic explanations involving OATP1B1 inhibition and, in some cases, BCRP inhibition. No analogous mechanism exists for zolpidem.

Context That Matters: When Co-Prescribed Patients Need Closer Monitoring

Low interaction risk does not mean zero clinical attention. Several scenarios warrant closer monitoring when a patient takes both rosuvastatin and zolpidem.

Advanced age. Patients over 65 metabolize zolpidem more slowly. The FDA reduced the recommended zolpidem dose for women and elderly patients in 2013, citing pharmacokinetic data showing women clear zolpidem approximately 45% more slowly than men at equivalent doses [5][10]. An older adult on both medications deserves a baseline assessment of fall risk and next-morning alertness, not because rosuvastatin worsens zolpidem effects, but because the clinical setting demands it.

Hepatic impairment. Both drugs undergo hepatic processing, though by different mechanisms. Rosuvastatin is contraindicated in patients with active liver disease or unexplained persistent transaminase elevations exceeding 3 times the upper limit of normal [4]. Zolpidem exposure increases substantially in cirrhotic patients, with AUC rising approximately 5-fold in one pharmacokinetic study (N=8) compared to matched controls [5]. A patient with compromised hepatic function on both drugs requires more frequent LFT monitoring and potentially lower doses of each.

CYP2C9 poor metabolizers. Roughly 1-3% of Caucasian and African American populations carry homozygous CYP2C9 loss-of-function alleles (*3/*3) [11]. These individuals clear both rosuvastatin and zolpidem's CYP2C9-dependent fraction more slowly. While neither drug depends predominantly on CYP2C9, the combined reduction in clearance through this shared minor pathway could theoretically produce modest increases in exposure for both drugs. No published pharmacogenomic study has specifically examined this combination in CYP2C9 poor metabolizers.

Polypharmacy. The real risk often comes from a third or fourth drug in the regimen. A patient taking rosuvastatin, zolpidem, and fluconazole (a strong CYP3A4 and moderate CYP2C9 inhibitor) faces a genuinely significant interaction, but the interaction is between fluconazole and zolpidem, not between the statin and the hypnotic. Dr. Mary Gutierrez, a clinical pharmacology researcher at the University of Maryland, has stated: "When we evaluate multi-drug regimens, the statin-hypnotic pair rarely drives the interaction. It is almost always a third agent, often an azole antifungal or macrolide antibiotic, that creates the pharmacokinetic bottleneck" [12].

How Rosuvastatin Compares to Other Statins for This Combination

Not all statins are equal when paired with zolpidem. This distinction matters clinically.

Simvastatin and lovastatin are extensively metabolized by CYP3A4, the same enzyme primarily responsible for zolpidem clearance. While simvastatin does not inhibit CYP3A4, patients taking simvastatin alongside CYP3A4 inhibitors already face elevated myopathy risk. Adding zolpidem to a regimen that includes simvastatin and a moderate CYP3A4 inhibitor creates a three-way metabolic competition that rosuvastatin avoids entirely.

Atorvastatin is also a CYP3A4 substrate, though its interaction profile is somewhat less severe than simvastatin's due to differences in extraction ratio and active metabolite contribution [13].

Pitavastatin and pravastatin, like rosuvastatin, have minimal CYP dependence. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends considering these hydrophilic statins for patients on complex multi-drug regimens precisely because of their lower CYP interaction burden [14].

For a patient already on zolpidem who needs statin therapy, rosuvastatin, pitavastatin, or pravastatin represent the pharmacokinetically simplest options. Rosuvastatin's potency advantage (5-10 mg rosuvastatin produces LDL-C reductions comparable to 40-80 mg atorvastatin per the STELLAR trial data) makes it a practical first choice in this scenario [15].

Patient Counseling Points

Patients asking about this combination deserve direct, specific answers. Here are the key counseling messages.

Take rosuvastatin at any consistent time of day. Take zolpidem immediately before bed, only when you can commit to 7-8 hours of sleep. These timing patterns are independent of each other.

Report unexplained muscle pain, tenderness, or weakness promptly. This applies to all statin therapy regardless of co-medications. The JUPITER trial (N=17,802) found myalgia rates of 7.6% with rosuvastatin 20 mg versus 6.6% with placebo over a median 1.9 years of follow-up, confirming that muscle symptoms occur but are often not drug-related [16].

Do not drink alcohol with zolpidem. Alcohol potentiates both sedation and next-morning impairment. This guidance applies regardless of statin use.

If your physician adds a new medication (especially antifungals, antibiotics, or HIV medications), request a new drug interaction check. The interaction risk with this combination comes from what else enters the regimen, not from the statin-hypnotic pair itself.

Women and adults over 65 should use the lower FDA-recommended zolpidem dose (5 mg immediate-release or 6.25 mg extended-release) regardless of concomitant statin therapy [10].